RE:News Claritas and Salzman to create
QUOTE from the article some of you D/T are going to chasing upon entry.
Claritas Pharmaceuticals (formerly Kalytera Therapeutics) and Salzman Group (SG) have entered a strategic collaboration agreement to accelerate the development of Claritas’ nitric oxide-releasing compound, R-107, for the treatment of Covid-19, influenza and other viral infections.
Claritas also plans to sign these agreements with other companies to conserve capital and speed up the development.
Partnering with companies for manufacturing R-107, as well as for designing and concluding clinical studies, Claritas will demonstrate its safety and efficacy in treating the infections.
Under the agreement, Salzman Group will provide its full capabilities to Claritas, including its expertise in working with nitric oxide and nitric oxide-releasing compounds.
WORKINMONTANA wrote: From the Kalyteran.co webpage.
[url=https://kalyteran.co/index.php?/topic/662-news-claritas-and-salzman-to-create-nitric-oxide-releasing-compound-for-covid-19/]https://kalyteran.co/index.php?/topic/662-news-claritas-and-salzman-to-create-nitric-oxide-releasing-compound-for-covid-19/[/url]
https://www.pharmaceutical-technology.com/news/claritas-salzman-nitric-oxide/
https://clarita.ca/index.php/articles/2-uncategorised/28-is-r-107-the-answer-to-the-covid-crisis
Claritas Therapeutics, a cutting edge R & D company with laboratories in Israel and Massachusetts is currently working on a combined treatment/anti viral application that can not only treat the damage COVID 19 has done to the lungs and organs but, also inhibit the replication of the genome responsible for infecting the human host.
Their Nitric Oxide prodrug, Radikal 107 https://kalyteran.co/kalytera/index.php/kalytera-and-r-107 has been enormously successful in large animal testing and, is about to enter Phase one human trials early in the New Year. The FDA has designated R-107 for Fast Track and the company will be applying for breakthrough therapy designation soon.
Robert Farrell, the CEO of Claritas Therapeutics has called R-107 a potential "game changer in the field of medical treatment for both Sars Cov Viruses and lung injuries" and has stated "Problems associated with making successful vaccines, and in particular, vaccines for Corona Viruses are varied and serious and will probably dog any potential global vaccine candidate far into the future. Having a treatment such as ours to work alongside them, just for the COVID application, is an extremely valuable tool."